Immunome (IMNM) Current Assets (2019 - 2026)

Immunome's Current Assets history runs 8 years deep, the most recent figure standing at $594.3 million for Q1 2026.

• Quarterly Current Assets rose 83.92% year-over-year to $594.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $594.3 million (up 83.92% YoY) and the FY2025 annual result came in at $660.8 million, up 198.54% from the prior year.
• Current Assets was $594.3 million for Q1 2026 at Immunome, down from $660.8 million in the prior quarter.
• Across five years, Current Assets topped out at $660.8 million in Q4 2025 and bottomed at $22.6 million in Q4 2022.
• A 5-year average of $215.1 million and a median of $221.3 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets plunged 60.01% — and 2024, when it surged 619.23%.
• Immunome's Current Assets stood at $22.6 million in 2022, then surged by 538.89% to $144.7 million in 2023, then surged by 52.96% to $221.3 million in 2024, then soared by 198.54% to $660.8 million in 2025, then dropped by 10.06% to $594.3 million in 2026.
• Business Quant data shows IMNM's Current Assets at $594.3 million in Q1 2026, $660.8 million in Q4 2025, and $279.9 million in Q3 2025.